IOVANCE BIOTHERAPEUTICS INC's ticker is IOVA and the CUSIP is 462260100. A total of 256 filers reported holding IOVANCE BIOTHERAPEUTICS INC in Q1 2021. The put-call ratio across all filers is 0.42 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $547,267 | -35.2% | 120,279 | +0.2% | 0.17% | -31.9% |
Q2 2023 | $845,001 | +27.0% | 120,029 | +10.2% | 0.25% | +21.0% |
Q1 2023 | $665,248 | +18.8% | 108,879 | +24.2% | 0.21% | +7.7% |
Q4 2022 | $560,084 | +27.3% | 87,650 | +90.6% | 0.20% | +25.0% |
Q3 2022 | $440,000 | -13.4% | 45,977 | 0.0% | 0.16% | -10.9% |
Q2 2022 | $508,000 | -18.8% | 45,977 | +22.3% | 0.18% | -6.4% |
Q1 2022 | $626,000 | -18.3% | 37,600 | -6.2% | 0.19% | -4.1% |
Q4 2021 | $766,000 | -47.2% | 40,100 | -31.8% | 0.20% | -44.4% |
Q3 2021 | $1,450,000 | -4.0% | 58,800 | +1.3% | 0.35% | +3.2% |
Q2 2021 | $1,510,000 | +12.1% | 58,050 | +36.4% | 0.34% | -8.1% |
Q1 2021 | $1,347,000 | -30.2% | 42,550 | +2.3% | 0.37% | -36.0% |
Q4 2020 | $1,930,000 | +68.7% | 41,600 | +19.7% | 0.58% | +33.8% |
Q3 2020 | $1,144,000 | +40.2% | 34,750 | +16.9% | 0.43% | +36.7% |
Q2 2020 | $816,000 | +130.5% | 29,735 | +151.2% | 0.32% | +87.0% |
Q1 2020 | $354,000 | +46.3% | 11,835 | +35.5% | 0.17% | +72.4% |
Q4 2019 | $242,000 | – | 8,735 | – | 0.10% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
MHR Fund Management | 11,997,103 | $84,459,605 | 11.88% |
MPM BioImpact LLC | 2,950,118 | $20,768,831 | 4.18% |
Perceptive Advisors | 14,036,410 | $98,816,326 | 2.86% |
Velan Capital Investment Management LP | 240,000 | $1,689,600 | 1.57% |
Parametrica Management Ltd | 96,500 | $679,360 | 1.31% |
Boxer Capital, LLC | 3,705,133 | $26,084 | 1.21% |
Soleus Capital Management, L.P. | 1,239,777 | $8,728,030 | 0.97% |
Opaleye Management Inc. | 421,000 | $2,963,840 | 0.71% |
683 Capital Management, LLC | 1,400,000 | $9,856,000 | 0.71% |
RICE HALL JAMES & ASSOCIATES, LLC | 1,758,759 | $12,381,665 | 0.70% |